Search clinical trials for: Antiparkinson Agents

Total 186953 results

Boehringer Ingelheim

Completed

A Study in Patients Suffering From Idiopathic Restless Legs Syndrome Who Responded to a Preceding, 6-month Treatment With Open-label Pramipexole Including Titration (0.125, 0.25, 0.5, 0.75 mg Orally q.n.)

Restless Legs Syndrome

Germany
Boehringer Ingelheim

Completed

A Phase IV Trial With Pramipexole to Investigate the Effects on RLS Symptoms and Sleep Disturbance in Patients With RLS

Restless Legs Syndrome

Denmark, Finland, Germany, Ireland, Italy, Norway, Spain, Sweden, United Kingdom
Stanford University
National Alliance for Research on Schizophrenia and Depression

Terminated

Imaging the Nucleus Accumbens in Major Depressed Patients 'Treated With Pramipexole

Depression

United States
Boehringer Ingelheim

Completed

Dose Finding Study of Pramipexole (Sifrol) in Patients With Idiopathic Restless Legs Syndrome (RLS)

Restless Legs Syndrome

Finland
Boehringer Ingelheim

Completed

A 6 Week Trial to Study the Efficacy and Safety of a Starting Dose 0.25 mg Pramipexole (Mirapex) in Patients With RLS

Restless Legs Syndrome

United States
GlaxoSmithKline

Completed

A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment With Ropinirole PR as Adjunctive Therapy in Patients With Parkinson's Disease Who Are Not Optimally Controlled on L-Dopa

Parkinson Disease

China
Singapore General Hospital
Singapore University of Technology and Design

Completed

Combinational Rehabilitative Therapy and Functional Brain Imaging for Patients Recovering From Motor Stroke

Ischaemic Stroke

Singapore
Kasr El Aini Hospital

Unknown

Effect of Cabergoline on Endometrial Vascularity During IntraCytoplasmic Sperm Injection

Infertility

Egypt
GlaxoSmithKline

Completed

12-week Polysomnography Study of Ropinirole Controlled Release for Restless Legs Syndrome ((CR-RLS))

Restless Legs Syndrome | Restless Legs Syndrome (RLS)

United States
Otsuka Pharmaceutical Co., Ltd.

Completed

A Placebo- and Ropinirole-Controlled Study for SPM 962 in Advanced Parkinson's Disease Patients

Parkinson's Disease

Japan
Stanford University
GlaxoSmithKline; Duke University

Completed

Ropinirole Controlled Release (CR) as an Adjunctive Agent in the Treatment of Major Depression

Depressive Disorder, Major

United States
Pfizer

Completed

Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease.

Parkinson Disease

United States, Argentina, Mexico, Puerto Rico
SOM Innovation Biotech SA
Hospital Vall d'Hebron

Completed

Study of SOM0226 in Familial Amyloid Polyneuropathy

Familial Amyloid Polyneuropathy (FAP)

Spain
Roxane Laboratories

Completed

A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Under Fed Conditions

Parkinson's Disease | Restless Leg Syndrome
Benha University

Completed

Diosmin Versus Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome (infertility)

Infertility

Egypt
University Hospital, Akershus
Solvay Pharmaceuticals

Completed

Continuous Delivery of Levodopa in Patients With Advanced Idiopathic Parkinsons Disease - Cost-benefit

Parkinson Disease

Norway
National Institute of Neurological Disorders and...

Completed

Talampanel to Treat Parkinson's Disease

Parkinson Disease

United States
Vanderbilt University Medical Center
United States Department of Defense

Completed

Social Decision Making in Parkinson's Disease

Parkinson Disease

United States
University of Oxford

Completed

Pramipexole and Emotional Processing (PEP)

Emotions | Motivation | Dopamine | Reward

United Kingdom
Boehringer Ingelheim

Completed

Pramipexole in Out-patients With Idiopathic Restless Legs Syndrome (IRLS)

Restless Legs Syndrome

China
Boehringer Ingelheim

Completed

Long-term Safety Study of Open-label Pramipexole ER in Patients With Advanced PD

Parkinson Disease

Austria, Czech Republic, Hungary, India, Italy, Korea, Republic of, Philippines, Poland, Russian Federation, Slovakia, Spain, Sweden, Ukraine, United Kingdom
Boehringer Ingelheim

Completed

Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease (PD)

Parkinson Disease

United States, Austria, Finland, France, Germany, Italy, Japan, Spain, Sweden, United Kingdom
Boehringer Ingelheim

Completed

Efficacy and Safety of Pramipexole Compared to Placebo in the Treatment of Restless Legs Syndrome (RLS)

Restless Legs Syndrome

United States
Boehringer Ingelheim

Completed

Phase IV Trial With Pramipexole to Evaluate Safety and Efficacy in Patients With RLS Associated With Mood Disturbances

Depression | Restless Legs Syndrome

Finland, France, Germany, Ireland, Italy, Korea, Republic of, Spain, Sweden, United Kingdom
Augusta University
GlaxoSmithKline

Completed

SWITCH:Restless Legs Patients Switched to Ropinirole From Pramipexole

Restless Legs Syndrome

United States
Sheppard Pratt Health System
Lieber Institute for Brain Development (LIBD)

Unknown

Evaluate the Effects of Tolcapone on Cognitive and Behavioral Dysfunction in Patients With BI and NCD

Neurocognitive Disorders | Brain Injuries | Brain Injuries, Traumatic

United States
Roxane Laboratories

Completed

A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Und Fasted Conditions

Parkinson's Disease | Restless Leg Syndrome
GlaxoSmithKline

Completed

Ropinirole Tablets In Young Patients With Restless Legs Syndrome

Restless Legs Syndrome

United States, Belgium, France
University of Sao Paulo General Hospital

Completed

Cabergoline in Nonfunctioning Pituitary Adenomas

Pituitary Adenoma | Nonfunctioning Pituitary Adenoma

Brazil
Royan Institute

Completed

Compare the Efficacy of Human Albumin With Cabergoline to Prevent Ovarian Hyper Stimulation in Assisted Reproductive Technology (ART) Program

Ovarian Hyperstimulation Syndrome

Iran, Islamic Republic of
Medical University of South Carolina
National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Completed

Effects of Cortical Dopamine Regulation on Drinking, Craving, and Cognitive Control

Alcohol Use Disorder

United States
Region Skane
Lund University

Recruiting

Long-term Efficacy of Pramipexole in Anhedonic Depression (LONG-PRAXOL)

Depression | Anhedonia

Sweden
VA Office of Research and Development
Oregon Health and Science University

Recruiting

Preventing Levodopa Induced Dyskinesia in Parkinson's Disease With HMG-CoA Reductase Inhibitors (STAT-PD)

Parkinson Disease | Dyskinesia, Drug-Induced

United States
Knopp Biosciences

Completed

Study in Healthy Volunteers of the Bioavailability of Dexpramipexole Tablets and Food Effects

Healthy Volunteers

United States
Neuropsychiatric Research Institute, Fargo, North...

Withdrawn

Pramipexole for Binge Eating Disorder

Binge Eating Disorder
Boehringer Ingelheim

Completed

Profile of Depressive Symptoms in Parkinsons Disease

Depression | Parkinson Disease

Netherlands, Germany, Italy, Switzerland, Austria, France, Spain, United Kingdom
Mauro Manconi
University Hospital Inselspital, Berne; Cardiocentro Ticino

Completed

Autonomic Function and Cardiovascular Risk in Restless Legs Syndrome (AUTOREST)

Restless Legs Syndrome

Switzerland
National Institute of Neurological Disorders and...

Completed

Levetiracetam Treatment of L-dopa Induced Dyskinesias

Parkinson Disease | Dyskinesias

United States
Boehringer Ingelheim

Completed

Pramipexole in Untreated and Levodopa-treated Parkinson's Disease Patients

Parkinson Disease
Boehringer Ingelheim

Completed

a PMS on Safety Profile of Pramipexole in Chinese Parkinson Disease Patients

Parkinson Disease

China
Boehringer Ingelheim

Completed

A Randomized, Double-blind, Active (Pramipexole 0.5 mg Tid) and Placebo Controlled, Study of Pramipexole Given 0.5 mg and 0.75 mg Bid Over 12-week Treatment in Early Parkinson's Disease (PD) Patients

Parkinson Disease

United States
Boehringer Ingelheim

Completed

Efficacy and Safety of Pramipexole (PPX) in Moderate to Severe Idiopathic Restless Legs Syndrome (RLS) Patients

Restless Legs Syndrome

Germany, Austria, Netherlands, Norway, Sweden
Oregon Health and Science University
Boehringer Ingelheim

Completed

Effects of a Dopamine Agonist on Pharmacodynamics of Levodopa in Parkinson's Disease (DALI)

Parkinson's Disease

United States
Rush University Medical Center

Completed

Levodopa Response and Gut Microbiome in Patients With Parkinson's Disease

Parkinson Disease

United States
Western University, Canada

Unknown

A Trial of tPCS on Parkinson's Disease OFF State

Parkinson Disease

Canada
GlaxoSmithKline

Completed

RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole

Restless Legs Syndrome | Restless Legs Syndrome (RLS)

Spain, United States, Belgium, Sweden, Australia, Netherlands, United Kingdom, Italy, Austria, Germany, Denmark, France, Norway
University of Chicago

Recruiting

A Clinical Trial of Tolcapone in Obsessive Compulsive Disorder

Obsessive-Compulsive Disorder | OCD

United States
University of Pennsylvania
National Institute on Drug Abuse (NIDA)

Completed

Neural Substrates in Nicotine Withdrawal

Tobacco Use Disorder

United States
Orion Corporation, Orion Pharma

Completed

Comtess® Versus Cabaseril® as Add-on to Levodopa in the Treatment of Parkinsonian Patients Suffering From Wearing- Off.

Parkinson's Disease

Germany
Phoenicia BioScience
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

The BENeFiTS Trial in Beta Thalassemia Intermedia (PB04-001)

Sickle Cell Disease | Beta Thalassemia Intermedia

United States, Canada

Search clinical trials for: Antiparkinson Agents

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Georgia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations